It remains to be seen how revolutionary bioresorbable devices will be in interventional cardiology, according to experts who discussed the new scaffolds, now in clinical trials, at the Transcatheter Cardiovascular Therapeutics meeting. Logic and data from abroad suggest the new approach will ultimately be widely adopted, said Dr. Antonio Colombo, who noted there are technical challenges associated with the new devices. But Dr. David Hildick-Smith sees them as a niche tool for a small portion of patients.

Related Summaries